Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...